nejm retatrutide 2023年度回顧】 Notable Articles of 2023 Day 3: Triple–Hormone-Receptor Agonist for Obesity — A Phase 2 Trial. N Engl J Med 2023; 389:514-526. 製圖：Sardinosis Retatrutide Triple Agonist Research Peptide

Results May Vary : Individual results will vary based on factors including age, starting weight, baseline metabolic health, consistency of use, adherence to the Healthy Eating Guide, physical activity level, genetic factors, current medications, and other individual variables

doi: 10.3389/fendo.2019.00051 182 MieczkowskaAIrwinNFlattPRChappardDMabilleauG

doi: 10.1111/j.1463-1326.2008.01018.x [DOI] [PubMed] [Google Scholar] 36.AstraZeneca Pharmaceuticals LP

Tan HC et al

Science Translational Medicine, 6 (265), 265sr6265sr6

Studies have examined retatrutide in preclinical and clinical contexts involving glucose regulation, energy balance, and body weight biology